The Movement Disorder Society

The International Parkinson and Movement Disorder Society (MDS) Continues to Caution Against Unproven Cell-Based Therapies for Parkinson's Disease

Retrieved on: 
Tuesday, February 9, 2021
Branches of biology, Biology, Medicine, Biotechnology, Stem cells, The Movement Disorder Society, Cell biology, Parkinson's disease, Stem-cell therapy, Unified Parkinson's disease rating scale, Myelodysplastic syndrome

Theoretically, cell-based therapies, including the use of stem cells, could be used to replace or repair the cells lost or damaged in the disease process, thereby improving symptoms.

Key Points: 
  • Theoretically, cell-based therapies, including the use of stem cells, could be used to replace or repair the cells lost or damaged in the disease process, thereby improving symptoms.
  • Several business enterprises worldwide offer 'stem cell therapies' for PD, making unsubstantiated claims of considerable benefit to the patient.
  • Read the full MDS statement and position paper cautioning against unproven cell-based therapies for Parkinson's disease.
  • About the International Parkinson and Movement Disorder Society: The International Parkinson and Movement Disorder Society (MDS), an international society of over 10,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research.

Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at the MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience

Retrieved on: 
Tuesday, September 8, 2020
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Huntington's disease, Organ systems, Health, Neurological disorders, Articles, Deutetrabenazine, Syndromes, RTT, Tardive dyskinesia, Teva Pharmaceuticals, The Movement Disorder Society, Tetrabenazine

Teva Neuroscience, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new study data on AUSTEDO (deutetrabenazine) will be presented at the International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2020) and during the Psych Congress 2020 Virtual Experience.

Key Points: 
  • Teva Neuroscience, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new study data on AUSTEDO (deutetrabenazine) will be presented at the International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2020) and during the Psych Congress 2020 Virtual Experience.
  • All abstracts presented at MDS Virtual Congress 2020 will be published in the Movement Disorders journal e-supplement and displayed as an e-poster in the 2020 Virtual Poster Hall.
  • Abstracts at the Psych Congress 2020 Virtual Experience will be available in the virtual exhibit hall.
  • AUSTEDO is indicated for the treatment of chorea associated with Huntingtons disease and for the treatment of tardive dyskinesia in adults.